Drug-induced parkinsonism

被引:36
作者
Susatia, Frandy [1 ]
Fernandez, Hubert H. [1 ]
机构
[1] McKnight Brain Inst, Gainesville, FL 32610 USA
关键词
MOVEMENT-DISORDERS; RATING-SCALE; EXTRAPYRAMIDAL SYNDROMES; RECEPTOR OCCUPANCY; INDUCED PSYCHOSIS; DOUBLE-BLIND; DISEASE; CLOZAPINE; ANTIPSYCHOTICS; DOPAMINE;
D O I
10.1007/s11940-009-0019-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Drug-induced parkinsonism (DIP) is condition that mimics Parkinson's disease. Characterized mainly by rigidity and bradykinesia, it has less prominent tremor and gait instability. DIP is generally caused by lipophilic drugs that "block" dopamine D2 receptors in the brain, although presynaptic dopamine depletion, false transmitters, mitochondrial respiratory chain dysfunction, and overactivity in the gamma-aminobutyric acid (GABA)ergic system or cholinomimetic action have also been postulated as possible mechanisms. The onset of DIP is acute to subacute. It is more common in women and has a bimodal age distribution. Other diseases that can resemble DIP include neuropsychiatric conditions (eg, depression, negative symptoms of schizophrenia) and Wilson's disease. Physicians may be able to prevent DIP by prescribing neuroleptic agents appropriately and with caution. The risk of DIP is presumably lower with the use of "atypical" antipsychotic agents but it is not eliminated, especially in those most vulnerable to parkinsonism (eg, the elderly or cognitively impaired). The best treatment is discontinuation of the provoking medication. Prospective studies are needed to further define the mechanism of DIP, identify individual susceptibility, determine the impact of atypical antipsychotic agents, and develop further treatment options for those unable to stop the offending agent.
引用
收藏
页码:162 / 169
页数:8
相关论文
共 62 条
[1]   UNSUSPECTED, SURREPTITIOUS DRUG-INDUCED PARKINSONISM [J].
ALBANESE, A ;
COLOSIMO, C ;
BENTIVOGLIO, AR ;
BERGONZI, P .
NEUROLOGY, 1992, 42 (02) :459-459
[2]   Understanding drug-induced parkinsonism - Separating pearls from oy-sters [J].
Alvarez, Maria Victoria G. ;
Evidente, Virgilio Gerald H. .
NEUROLOGY, 2008, 70 (08) :E32-E34
[3]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[4]   A SURVEY OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS [J].
AYD, FJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1961, 175 (12) :1054-&
[5]   Clozapine in Parkinson's disease tremor - Effects of acute and chronic administration [J].
Bonuccelli, U ;
Ceravolo, R ;
Salvetti, S ;
D'Avino, C ;
Del Dotto, P ;
Rossi, G ;
Murri, L .
NEUROLOGY, 1997, 49 (06) :1587-1590
[6]   The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism [J].
Booij, J ;
Speelman, JD ;
Horstink, MWIM ;
Wolters, EC .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (03) :266-272
[7]   Implications of the CATIE trial on treatment: Extrapyramidal symptoms [J].
Casey, Daniel E. .
CNS SPECTRUMS, 2006, 11 (07) :25-31
[8]  
Casey DE, 2004, J CLIN PSYCHIAT, V65, P25
[9]   Manual for the Extrapyramidal Symptom Rating Scale (ESRS) [J].
Chouinard, G ;
Margolese, HC .
SCHIZOPHRENIA RESEARCH, 2005, 76 (2-3) :247-265
[10]  
Claxton KL., 2007, J PHARM PRACT, V20, P415, DOI [DOI 10.1177/0897190007310514, 10.1177/0897190007310514]